Targeting histone deacetylases: Development of vorinostat for the treatment of cancer

Epigenomics

Volumn 2, Issue 3, 2010, Pages 457-465

  Richon, Victoria M ^a  

^a EPIZYME INC   (United States)

Author keywords

cancer therapeutic; chromatin modifying enzymes; histone deacetylase; protein acetylation; vorinostat

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BELINOSTAT; BENZAMIDE; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DEXAMETHASONE; ENTINOSTAT; ERLOTINIB; FLUOROURACIL; GEMCITABINE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; LENALIDOMIDE; MELPHALAN; MOCETINOSTAT; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; PACLITAXEL; PANOBINOSTAT; PREDNISONE; PROTEASOME INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; ROMIDEPSIN; SALINOSPORAMIDE A; SNDX 275; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BRAIN METASTASIS; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CHEMICAL STRUCTURE; CLINICAL TRIAL; COLON CANCER; DIARRHEA; DRUG APPROVAL; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; FATIGUE; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; GLIOBLASTOMA; GROWTH INHIBITION; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CANCER; LEUKEMIA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MASS SPECTROMETRY; MESOTHELIOMA; MONOTHERAPY; MOUSE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NAUSEA; NONHUMAN; OROPHARYNX CANCER; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; QT PROLONGATION; REVIEW; SIDE EFFECT; SKIN LYMPHOMA; SQUAMOUS CELL CARCINOMA; T CELL LYMPHOMA; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THYROID CANCER; TREATMENT OUTCOME; TUMOR GROWTH; VOMITING;

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HYDROXAMIC ACIDS; LYSINE; NEOPLASMS;

EID: 77954100842     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.10.20     Document Type: Review

References (73)

1. Richon VM, Webb Y, Merger R et al.: Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc. Natl Acad. Sci. USA 93(12), 5705-5708 (1996).
2. Richon VM, Emiliani S, Verdin E et al.: A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl Acad. Sci. USA 95(6), 3003-3007 (1998).
3. Marks PA, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK: Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1, 194-202 (2001).
4. Richon VM, Garcia-Vargas J, Hardwick JS: Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer Lett. 280(2), 201-210 (2009).
5. Yang XJ, Seto E: The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat. Rev Mol. Cell Biol. 9, 206-218 (2008).
6. Choudhary C, Kumar C, Gnad F et al.: Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325(5942), 834-840 (2009).
7. Zhou Q, Chaerkady R, Shaw PG, Kensler TW, Pandey A, Davidson NE: Screening for therapeutic targets of vorinostat by SILAC-based proteomic analysis in human breast cancer cells. Proteomics 10(5), 1029-1039 (2010).
8. Gayther SA, Batley SJ, Linger L et al.: Mutations truncating the EP300 acetylase in human cancers. Nat. Genet. 24(3), 300-303 (2000).
9. Choi JH, Kwon HJ, Yoon BI et al.: Expression profle of histone deacetylase 1 in gastric cancer tissues. Jpn. J. Cancer Res. 92(12), 1300-1304 (2001).
10. Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN: Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59(2), 177-189 (2004).
11. Spurling CC, Godman CA, Noonan EJ, Rasmussen TP, Rosenberg DW, Giardina C: HDAC3 overexpression and colon cancer cell proliferation and differentiation. Mol. Carcinog. 47(2), 137-147 (2008).
12. Jin KL, Pak JH, Park JY et al.: Expression profle of histone deacetylases 1, 2 and 3 in ovarian cancer tissues. J. Gynecol. Oncol. 19(3), 185-190 (2008).
13. Chang HH, Chiang CP, Hung HC, Lin CY, Deng Y T, Kuo MY: Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients. Oral Oncol. 45(7), 610-614 (2009).
14. Dhordain P, Lin RJ, Quief S et al.: The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression. Nucleic Acids Res. 26(20), 4645-4651 (1998).
15. Grignani F, De Matteis S, Nervi C et al.: Fusion proteins of the retinoic acid receptor-a recruit histone deacetylase in promyelocytic leukaemia. Nature 391(6669), 815-818 (1998).
16. Ropero S, Fraga MF, Ballestar E et al.: A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat. Genet. 38(5), 566-569 (2006).
17. Hanigan CL, van Engeland M, De Bruine AP et al.: An inactivating mutation in HDAC2 leads to dysregulation of apoptosis mediated by APAF1. Gastroenterology 135(5), 1654-1664.e2 (2008).
18. Glaser KB, Li J, Staver MJ, Wei RQ, Albert DH, Davidsen SK: Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem. Biophys. Res. Commun. 310(2), 529-536 (2003).
19. Huang BH, Laban M, Leung CH et al.: Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ. 12(4), 395-404 (2005).
20. Senese S, Zaragoza K, Minardi S et al.: Role for histone deacetylase 1 in human tumor cell proliferation. Mol. Cell Biol. 27(13), 4784-4795 (2007).
21. Piekarz RL, Bates SE: Epigenetic modifers: basic understanding and clinical development. Clin. Cancer Res. 15(12), 3918-3926 (2009).
22. Bradner JE, West N, Grachan ML et al.: Chemical phylogenetics of histone deacetylases. Nat. Chem. Biol. 6(3), 238-243 (2010).
23. Olsen EA, Kim YH, Kuzel TM et al.: Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 25(21), 3109-3115 (2007).
24. Campas-Moya C: Romidepsin for the treatment of cutaneous T-cell lymphoma. Drugs Today (Barc.) 45(11), 787-795 (2009).
25. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK: Gene expression profling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. 2(2), 151-163 (2003).
26. Mitsiades CS, Mitsiades NS, McMullan CJ et al.: Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc. Natl Acad. Sci. USA 101(2), 540-545 (2004).
27. Peart MJ, Smyth GK, van Laar RK et al.: Identifcation and functional signifcance of genes regulated by structurally different histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA 102(10), 3697-3702 (2005).
28. LaBonte MJ, Wilson PM, Fazzone W, Groshen S, Lenz HJ, Ladner RD: DNA microarray profling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. BMC Med. Genomics 2, 67 (2009).
29. Barlev NA, Liu L, Chehab NH et al.: Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol. Cell. 8(6), 1243-1254 (2001).
30. Bereshchenko OR, Gu W, Dalla-Favera R: Acetylation inactivates the transcriptional repressor BCL6. Nat. Genet. 32(4), 606-613 (2002).
31. Wang R, Cherukuri P, Luo J: Activation of Stat3 sequence-specifc DNA binding and transcription by p300/CREB-binding protein-mediated acetylation. J. Biol. Chem. 280(12), 11528-11534 (2005).
32. Frew AJ, Johnstone RW, Bolden JE: Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett. 280(2), 125-133 (2009).
33. Shao Y, Gao Z, Marks PA, Jiang X: Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA 101(52), 18030-18035 (2004).
34. Deroanne CF, Bonjean K, Servotte S et al.: Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21(3), 427-436 (2002).
35. Cohen LA, Amin S, Marks PA, Rifkind RA, Desai D, Richon VM: Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA). Anticancer Res. 19(6B), 4999-5005 (1999).
36. Cohen LA, Marks PA, Rifkind RA et al.: Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors. Anticancer Res. 22(3), 1497-1504 (2002).
37. Desai D, Das A, Cohen L, el-Bayoumy K, Amin S: Chemopreventive effcacy of suberoylanilide hydroxamic acid (SAHA) against 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in female A/J mice. Anticancer Res. 23(1A), 499-503 (2003).
38. Butler LM, Agus DB, Scher HI et al.: Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 60(18), 5165-5170 (2000).
39. Spiller SE, Ravanpay AC, Hahn AW, Olson JM: Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma. J. Neurooncol. 79(3), 259-270 (2006).
40. Fazzone W, Wilson PM, Labonte MJ, Lenz HJ, Ladner RD: Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fuoropyrimidines in colon cancer cells. Int. J. Cancer 125(2), 463-473 (2009).
41. Campbell RA, Sanchez E, Steinberg J et al.: Vorinostat enhances the antimyeloma effects of melphalan and bortezomib. Eur. J. Haematol. 84(3), 201-211 (2010).
42. He LZ, Tolentino T, Grayson P et al.: Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J. Clin. Invest. 108(9), 1321-1330 (2001).
43. Lindemann RK, Newbold A, Whitecross KF et al.: Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc. Natl Acad. Sci. USA 104(19), 8071-8076 (2007).
44. Kerr JS, Galloway S, Lagrutta A et al.: Nonclinical safety assessment of the histone deacetylase inhibitor vorinostat. Int. J. Toxicol. 29(1), 3-19 (2010).
45. Bots M, Johnstone RW: Rational combinations using HDAC inhibitors. Clin. Cancer Res. 15(12), 3970-3977 (2009).
46. Baylin SB: DNA methylation and gene silencing in cancer. Nat. Clin. Pract. Oncol. 2(Suppl. 1), S4-S11 (2005).
47. Cameron EE, Bachman KE, Myöhänen S, Herman JG, Baylin SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21(1), 103-107 (1999).
48. Kumagai T, Wakimoto N, Yin D et al.: Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int. J. Cancer 121(3), 656-665 (2007).
49. Venturelli S, Armeanu S, Pathil A: Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. Cancer 109(10), 2132-2141 (2007).
50. Silverman LB, Verma A, Odchimar-Ressig R et al.: A Phase I/II study of vorinostat, an oral histone deacetylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Initial results of the Phase I trial: a New York cancer consortium study. J. Clin Oncol. 26, 7000 (2008) (ASCO Meeting Abstracts).
51. DiGennaro E, Bruzzese F, Pepe S et al.: Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic anti-tumor effect in combination with 5FU or raltitrexed. Cancer Biol. Ther. 8(9), 782-791 (2009).
52. Fakih MG, Pendyala L, Fetterly G et al.: A Phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fuorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. Clin. Cancer Res. 15(9), 3189-3195 (2009).
53. Wilson PM, El-Khoueiry A, Iqbal S et al.: A Phase I/II trial of vorinostat in combination with 5-fuorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. Cancer Chemother. Pharmacol. 65(5), 979-988 (2010).
54. Laubach JP, Mitsiades CS, Mahindra A: Novel therapies in the treatment of multiple myeloma. J. Natl Compr. Canc. Netw. 7(9), 947-960 (2009).
55. Adams J: The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5(5), 417-421 (2004).
56. Nawrocki ST, Carew JS, Pino MS et al.: Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res. 66, 3773-3781 (2006).
57. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP: The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115(6), 727-738 (2003).
58. Denlinger CE, Rundall BK, Jones DR: Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species. J. Thorac. Cardiovasc. Surg. 128(5), 740-748 (2004).
59. Pei XY, Dai Y, Grant S: Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin. Cancer Res. 10(11), 3839-3852 (2004).
60. Yu C, Rahmani M, Conrad D, Subler M, Dent P, Grant S: The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 102(10), 3765-3774 (2003).
61. Badros A, Burger AM, Philip S et al.: Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin. Cancer Res. 15(16), 5250-5257 (2009).
62. Siegel D, Hussein M, Belani C et al.: Vorinostat in solid and hematologic malignancies. J. Hematol. Oncol. 2, 31 (2009).
63. Tan J, Cang S, Ma Y, Petrillo RL, Liu D: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J. Hematol. Oncol. 3, 5 (2010).
64. Cang S, Ma Y, Liu D: New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. J. Hematol. Oncol. 2, 22 (2009).
65. Munster PN, Rubin EH, van Belle S et al.: A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer. Clin. Cancer Res. 15(22), 7077-7084 (2009).
66. Kelly WK, O'Connor OA, Krug LM et al.: Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. 23, 3923-3931 (2005).
67. O'Connor OA, Heaney ML, Schwartz L et al.: Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J. Clin. Oncol. 24(1), 166-173 (2006).
68. Garcia-Manero G, Yang H, Bueso-Ramos C et al.: Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 111(3), 1060-1066 (2008).
69. Galanis E, Jaeckle KA, Maurer MJ et al.: Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J. Clin. Oncol. 27(12), 2052-2058 (2009).
70. Fantin VR, Loboda A, Paweletz CP et al.: Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res. 68, 3785-3794 (2008).
71. Duvic M, Talpur R, Ni X et al.: Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109(1), 31-39 (2007). (Pubitemid 46053039)
72. Watanabe T, Kato H, Kobayashi Y et al.: Potential effcacy of the oral histone deacetylase inhibitor vorinostat in a Phase I trial in follicular and mantle cell lymphoma. Cancer Sci. 101(1), 196-200 (2010).
73. Paik PK, Krug LM: Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials. J. Thorac. Oncol. 5, 275-279 (2010).